Share on StockTwits

Cytosorbents Corp (NASDAQ:CTSO) Director Al Kraus unloaded 50,000 shares of the company’s stock on the open market in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $0.25, for a total value of $12,500.00. Following the completion of the sale, the director now directly owns 1,393,631 shares in the company, valued at approximately $348,408. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of Cytosorbents Corp (NASDAQ:CTSO) traded down 2.96% during mid-day trading on Wednesday, hitting $0.2231. 417,056 shares of the company’s stock traded hands. Cytosorbents Corp has a one year low of $0.09 and a one year high of $0.35. The stock’s 50-day moving average is $0.2 and its 200-day moving average is $0.24. The company’s market cap is $69.3 million.

Cytosorbents Corp (NASDAQ:CTSO) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). Analysts expect that Cytosorbents Corp will post $-0.03 EPS for the current fiscal year.

Separately, analysts at HC Wainwright initiated coverage on shares of Cytosorbents Corp in a research note on Monday, August 18th. They set a “buy” rating and a $1.00 price target on the stock.

CytoSorbents Corporation is a development stage critical care focused company using blood purification to treat life-threatening illnesses.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.